ILMN Illumina, Inc.
A real consumables franchise, but $269 assumes growth Illumina has not shown since 2021.
The story
Illumina is still the dominant short-read sequencing platform. Its moat is the large installed base, locked-in consumables revenue (the razor/blade model) and workflow standards in clinical genomics. After the GRAIL write-offs and spin-off, and a few years of flat-to-down revenue hurt by China export restrictions, academic funding pressure and repricing to NovaSeq X, it is a mature franchise trying to restart growth through clinical oncology, multiomics and proteomics. The share price assumes that restart succeeds and that margins return to pre-GRAIL levels of about 30% or more.
I credit growth reaccelerating to 7% as clinical demand and the multiomics push offset weakness in China and academic budgets, and margins returning to the high-20s/low-30s Illumina earned before GRAIL. I don't assume the mid-30s peak returns because Element, Ultima, PacBio and MGI keep pressure on pricing. The 12-year horizon reflects a real consumables moat. Sales-to-capital is set above the reported 0.93 because that figure is inflated by acquired goodwill, and organic reinvestment needs are lighter. Even with these generous drivers my value probably stays well below $269, so the market is pricing in a growth runway I can't yet support.
Value drivers
| Revenue growth (Y1) | 7.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 12y |
| Target operating margin | 31.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.50 |
| Beta | 1.05 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 9.5% |
| Terminal WACC | 9.3% |
Valuation bridge
| PV of explicit FCFF | 8.60B |
| PV of terminal value | 9.14B |
| Equity value | 16.83B |
| ÷ shares → per share | $111.44 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 4.70B | 7.0% | 27.3% | 1.01B | 205.01M | 800.27M | 730.86M |
| 2 | 5.01B | 6.7% | 28.2% | 1.11B | 209.39M | 899.13M | 749.92M |
| 3 | 5.33B | 6.4% | 29.2% | 1.22B | 212.74M | 1.00B | 765.28M |
| 4 | 5.66B | 6.0% | 30.1% | 1.33B | 214.96M | 1.12B | 776.85M |
| 5 | 5.98B | 5.7% | 31.0% | 1.45B | 215.96M | 1.24B | 784.62M |
| 6 | 6.30B | 5.4% | 31.0% | 1.53B | 215.65M | 1.31B | 762.29M |
| 7 | 6.62B | 5.1% | 31.0% | 1.61B | 213.94M | 1.39B | 738.34M |
| 8 | 6.94B | 4.8% | 31.0% | 1.68B | 210.78M | 1.47B | 712.95M |
| 9 | 7.25B | 4.5% | 31.0% | 1.76B | 206.12M | 1.55B | 686.33M |
| 10 | 7.55B | 4.1% | 31.0% | 1.83B | 199.92M | 1.63B | 658.67M |
| 11 | 7.84B | 3.8% | 31.0% | 1.90B | 192.17M | 1.71B | 630.18M |
| 12 | 8.11B | 3.5% | 31.0% | 1.97B | 182.89M | 1.79B | 601.06M |
Key risks
- Low-cost sequencing competitors (Element, Ultima, MGI/Complete Genomics) erode consumable pricing and share
- China export restrictions and the unreliable entity listing permanently shrink a former growth market
- NIH and academic funding cuts depress instrument placements and pull-through
Catalysts
- Clinical oncology and genetic disease testing volumes driving higher consumables pull-through per NovaSeq X
- Multiomics and proteomics launches opening an incremental market beyond sequencing